List all clinical trials by discovery date. Accepts regular expressions in search.

GET /trials/?page=3
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 767,
    "next": "http://api.gregory-ms.com/trials/?page=4",
    "previous": "http://api.gregory-ms.com/trials/?page=2",
    "results": [
        {
            "trial_id": 416599,
            "title": "Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients",
            "summary": "<b>Conditions</b>:    Shingles;   Zoster<br /><b>Intervention</b>:    Biological: recombinant zoster vaccine<br /><b>Sponsor</b>:    Prof Patrice Lalive<br /><b>Not yet recruiting</b>",
            "published_date": "2022-10-27T12:00:00Z",
            "discovery_date": "2022-10-27T12:30:18.003110Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05596526?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 412930,
            "title": "An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis",
            "summary": "<p>EudraCT Number: 2017-004703-51<br />Sponsor Protocol Number: COMB157G2399<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-01-10<br />Medical condition: Multiple sclerosis<br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10048393<br />Term: Multiple sclerosis relapse<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DE\">DE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SK\">SK</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HU\">HU</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GB\">GB</a> (GB - no longer in EU/EEA), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/NL\">NL</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/AT\">AT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FR\">FR</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/PT\">PT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/ES\">ES</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/CZ\">CZ</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/SE\">SE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LT\">LT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/DK\">DK</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/FI\">FI</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/BE\">BE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/LV\">LV</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/GR\">GR</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004703-51/HR\">HR</a> (Ongoing)</p>",
            "published_date": null,
            "discovery_date": "2022-10-25T08:00:17.576790Z",
            "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2017-004703-51",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 412442,
            "title": "AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE...",
            "summary": "<p>EudraCT Number: 2016-002667-34<br />Sponsor Protocol Number: WA39085<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2020-03-06<br />Medical condition: Relapsing-remitting multiple sclerosis (MS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10039720<br />Term: Sclerosis multiple<br />Level: LLT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002667-34/PL\">PL</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002667-34/IT\">IT</a> (Ongoing)</p>",
            "published_date": null,
            "discovery_date": "2022-10-25T00:40:14.485582Z",
            "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2016-002667-34",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 412421,
            "title": "A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-\nArm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy\nand Safety of BG00012 and BIIB017 ...",
            "summary": "<p>EudraCT Number: 2018-000516-22<br />Sponsor Protocol Number: 800MS301<br />Sponsor Name: Biogen Idec Research Limited<br />Start Date: 2019-07-08<br />Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) <br />Disease: <br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10029205<br />Term: Nervous system disorders<br />Level: SOC<br />Version: 20.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Children, Adolescents, Under 18<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/PT\">PT</a> (Not Authorised), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/EE\">EE</a> (Prematurely Ended), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/HU\">HU</a> (Prematurely Ended)</p>",
            "published_date": null,
            "discovery_date": "2022-10-25T00:15:18.515701Z",
            "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2018-000516-22",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 407407,
            "title": "Turkish Version of F-2-MS",
            "summary": "<b>Conditions</b>:    Cultural Adaptation;   Reliability;   Validity;   Multiple Sclerosis;   Fatigue<br /><b>Intervention</b>:    Other: Cultural adaptation, reliability and validity<br /><b>Sponsor</b>:    Pamukkale University<br /><b>Not yet recruiting</b>",
            "published_date": "2022-10-21T12:00:00Z",
            "discovery_date": "2022-10-21T12:25:18.740122Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05590533?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 404355,
            "title": "Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis",
            "summary": "<b>Conditions</b>:    Multiple Sclerosis;   Neurogenic Bladder<br /><b>Interventions</b>:    Diagnostic Test: Urodynamic Study (Filling cystometry and pressure-flow study);   Diagnostic Test: Questionnaires;   Diagnostic Test: Uroflowmetry<br /><b>Sponsor</b>:    Koç University<br /><b>Recruiting</b>",
            "published_date": "2022-10-19T12:00:00Z",
            "discovery_date": "2022-10-19T12:50:08.887350Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05587101?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 404354,
            "title": "Teleassessment in Ataxic Multiple Sclerosis",
            "summary": "<b>Conditions</b>:    Ataxia;   Multiple Sclerosis<br /><b>Intervention</b>:    <br /><b>Sponsor</b>:    Hacettepe University<br /><b>Not yet recruiting</b>",
            "published_date": "2022-10-19T12:00:00Z",
            "discovery_date": "2022-10-19T12:50:08.884841Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05585541?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 403105,
            "title": "A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101",
            "summary": "<p>EudraCT Number: 2022-000253-92<br />Sponsor Protocol Number: EHP-101-MS02<br />Sponsor Name: Emerald Health Pharmaceuticals Inc.<br />Start Date: 2022-10-14<br />Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)<br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063400<br />Term: Secondary progressive multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000253-92/ES\">ES</a> (Ongoing)</p>",
            "published_date": null,
            "discovery_date": "2022-10-17T17:35:19.146681Z",
            "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000253-92",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 401170,
            "title": "Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis",
            "summary": "<b>Conditions</b>:    Multiple Sclerosis, Chronic Progressive;   High-Intensity Interval Training;   Motor Symptoms<br /><b>Interventions</b>:    Behavioral: HIIT;   Behavioral: MCT<br /><b>Sponsor</b>:    Klinik Valens<br /><b>Recruiting</b>",
            "published_date": "2022-09-30T12:00:00Z",
            "discovery_date": "2022-10-14T12:55:15.648650Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05562414?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 400545,
            "title": "Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Ofatunumab<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>",
            "published_date": "2022-10-13T12:00:00Z",
            "discovery_date": "2022-10-13T15:57:03.370462Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05576779?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        }
    ]
}